Skindex-29
Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.
Izvorni zapis
Citati kopirani doslovno iz izvornog zapisa metode. Ne impliciraju nikakvu provjeru na razini tvrdnje.
- Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. · DOI 10.1111/1523-1747.ep12365600
- Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440. · DOI 10.1001/archderm.133.11.1433
Uređene tvrdnje
Tvrdnje pohranjene u knjigu dokaza, svaka s vlastitom procjenom.
Ovaj prikaz ne izmišlja procjenu tvrdnje kada knjiga dokaza nema nijednu.
Povezane metode
Generirano iz grafa metode i prikazano kao strojno predložene relacije — ne implicira se nikakva tvrdnja dokaza.